PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012

_{//health-fitness.news-articles.net/content/2012/ .. quity-conference-on-tuesday-january-17-2012.html}
^{Published in Health and Fitness on Wednesday, January 11th 2012 at 11:26 GMT by Market Wire}  

PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on... -- ANNAPOLIS, Md., Jan. 11, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about PIP

ANNAPOLIS, Md., Jan. 11, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: [ PIP ]), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the Noble Financial Capital Markets Eighth Annual Equity Conference on Tuesday, January 17, 2012 at 3:30 pm EST in the Volga Room/Room 2 at the Hard Rock Hotel, Hollywood Florida. 

Mr. Richman will also be available to participate in one-on-one meetings at the conference.

Event:  Noble Financial Capital Markets 8th Annual Equity Conference
Date:  Tuesday, January 17, 2012
Place:  Hollywood, Florida; Hard Rock Hotel; Volga Room / Room 2
Time:  3:30 pm EST

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

• SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
• Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
• Recombinant BChE - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

In addition, pursuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the profits over 10 years from all sales of SIGA Technologies' ST-246, and related products, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox (once SIGA receives the first $40 million in net profits from sales of ST-246.) For more information about PharmAthene, please visit [ www.PharmAthene.com ].

SOURCE PharmAthene, Inc.

RELATED LINKS
[ http://www.pharmathene.com ]